163 related articles for article (PubMed ID: 34708307)
1. Clinical features and risk factors for early recurrence after esophagectomy following neoadjuvant chemotherapy for esophageal cancer.
Kurogochi T; Honda M; Takahashi K; Okamura A; Imamura Y; Yamashita K; Kamiya S; Hayami M; Mine S; Watanabe M
Surg Today; 2022 Apr; 52(4):660-667. PubMed ID: 34708307
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
3. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Okamura A; Matsuda S; Mayanagi S; Kanamori J; Imamura Y; Irino T; Kawakubo H; Mine S; Takeuchi H; Kitagawa Y; Watanabe M
Ann Surg Oncol; 2021 Feb; 28(2):1209-1216. PubMed ID: 32524457
[TBL] [Abstract][Full Text] [Related]
5. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery.
Oguma J; Ishiyama K; Kurita D; Kanematsu K; Fujii Y; Kubo K; Yamamoto S; Honma Y; Kato K; Daiko H
Esophagus; 2022 Apr; 19(2):214-223. PubMed ID: 34757482
[TBL] [Abstract][Full Text] [Related]
6. Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan.
Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
Esophagus; 2023 Jul; 20(3):465-473. PubMed ID: 37029845
[TBL] [Abstract][Full Text] [Related]
7. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.
Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H
Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967
[TBL] [Abstract][Full Text] [Related]
8. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery.
Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K
Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma.
Ma S; Yan T; Liu D; Wang K; Wang J; Song J; Wang T; He W; Bai J; Jin L; Chen X
Thorac Cancer; 2018 Feb; 9(2):310-315. PubMed ID: 29319236
[TBL] [Abstract][Full Text] [Related]
10. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H
Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M
In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376
[TBL] [Abstract][Full Text] [Related]
14. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
[TBL] [Abstract][Full Text] [Related]
15. High Preoperative Platelet to Lymphocyte Ratio Is Associated with a Greater Risk of Postoperative Complications and Hematogenous Recurrences in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Treatment.
Sasahara M; Kanda M; Shimizu D; Takami H; Inokawa Y; Hattori N; Hayashi M; Tanaka C; Fujiwara M; Nakayama G; Kodera Y
Dig Surg; 2023; 40(1-2):48-57. PubMed ID: 36893749
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of endoscopic response evaluation after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a nationwide validation study.
Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Kono K; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Esophagus; 2023 Jul; 20(3):455-464. PubMed ID: 36964333
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy for pT1a-m3/pT1b esophageal squamous cell carcinoma after endoscopic resection: Esophagectomy or chemoradiotherapy? A critical review.
Tsou YK; Lee CH; Le PH; Chen BH
Crit Rev Oncol Hematol; 2020 Mar; 147():102883. PubMed ID: 32014674
[TBL] [Abstract][Full Text] [Related]
18. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients.
Sohda M; Saito H; Kuriyama K; Yoshida T; Kumakura Y; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Sakai M; Miyazaki T; Fukuchi M; Kuwano H
In Vivo; 2019; 33(2):501-506. PubMed ID: 30804133
[TBL] [Abstract][Full Text] [Related]
19. Impact of Tumor Size on Survival Outcome in Esophageal Squamous Cell Carcinoma After Esophagectomy Following Neoadjuvant Chemotherapy.
Koterazawa Y; Oshikiri T; Goto H; Kato T; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Kakeji Y
Ann Surg Oncol; 2024 Apr; 31(4):2482-2489. PubMed ID: 38151622
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
